The FDA’s Decision Regarding The Pathway Forward For Cannabidiol (CBD)

Introduction: A Complex Regulatory Landscape For CBD

The cannabidiol (CBD) market has experienced explosive growth over the past decade, driven by increasing consumer demand, wellness trends, and expanding legalization of hemp-derived products.

However, regulatory clarity has not kept pace.

Despite widespread availability of CBD products in the U.S., the U.S. Food and Drug Administration continue to enforce strict rules regarding its use in foods, dietary supplements, and therapeutic products.

This creates a paradox:

• High consumer demand 
• Expanding commercial market 
• Limited regulatory approval pathways 

Understanding the FDA’s position is critical for businesses aiming to operate legally and sustainably in this evolving space.

What is the FDA’s current stance on CBD regulation in 2025?
The U.S. Food and Drug Administration (FDA) maintains that cannabidiol (CBD) cannot currently be marketed as a food ingredient or dietary supplement due to its prior approval as a drug ingredient. The agency has concluded that existing regulatory frameworks are insufficient and is working with Congress to establish a new, science-based pathway for CBD products.

Legal And Regulatory Background

The Impact of the 2018 Farm Bill

The Agriculture Improvement Act of 2018 legalized hemp (defined as cannabis with ≤0.3% THC), removing it from the Controlled Substances Act.

This milestone:

• Enabled large-scale hemp cultivation 
• Opened the market for hemp-derived CBD 
• Created widespread industry optimism 

However, it did not override FDA authority.

FDA Authority Under Federal Law

CBD remains regulated under:

• Federal Food, Drug, and Cosmetic Act 
• Public Health Service Act 

A critical legal barrier exists:

CBD is the active ingredient in Epidiolex, an FDA-approved drug.

Key Rule:
Any substance first approved as a drug cannot be added to foods or dietary supplements unless a specific regulatory exception is granted.

Regulatory Status Summary

FDA’s Enforcement Actions & Public Health Concerns

The FDA has taken a cautious, science-driven approach to CBD regulation.

Warning Letters & Market Oversight

Since 2015, the FDA has issued numerous warning letters to companies for:

• Unsubstantiated medical claims 
• Mislabeling of CBD content 
• Marketing CBD as a cure or treatment 

Key Safety Concerns Identified by FDA

The agency has raised several critical health risks:

• Liver toxicity with long-term use 
• Reproductive health effects (particularly in males) 
• Unknown risks for: 
  • Children 
  • Pregnant and breastfeeding women 
• Drug interactions with other medications 
• Animal feed risks, impacting: 
  • Milk 
  • Meat 
  • Eggs 

CBD Safety Risk Overview

Citizen Petitions & FDA’s Rejection

Three major industry organizations:

• Consumer Healthcare Products Association (CHPA) 
• Council for Responsible Nutrition (CRN) 
• Natural Products Association (NPA) 

submitted petitions requesting a legal pathway for CBD in dietary supplements.

FDA’s Decision

In 2023, the FDA formally rejected these petitions, citing:

• Lack of comprehensive safety data 
• Uncertainty around safe daily intake levels 
• Insufficient long-term exposure studies 

Key FDA Conclusion

Existing frameworks for food and supplements are not adequate for CBD regulation.

Why Current Regulatory Frameworks Are Insufficient

The FDA identified structural gaps in existing systems:

The Path Forward: FDA & Congressional Collaboration

The FDA has emphasized that Congressional action is required to move forward.

Proposed Future Regulatory Framework

The new pathway is expected to include:

1. Safety Thresholds

• Establish acceptable daily intake (ADI) 
• Define maximum dosage limits 

2. Labeling & Consumer Transparency

• Standardized labeling formats 
• Clear dosage instructions 
• Risk warnings for vulnerable groups 

3. Manufacturing & Quality Standards

• GMP compliance requirements 
• Batch testing and validation 
• Contaminant screening 

4. Protection of Vulnerable Populations

• Restrictions for: 
  • Children 
  • Pregnant women 
  • Elderly populations 

5. Animal Feed Regulation

• Assessment of CBD transfer into food products 
• Limits for livestock exposure 

Strategic Implications for Industry Stakeholders

Who Is Affected?

• CBD manufacturers 
• Dietary supplement companies 
• Food & beverage brands 
• Pharmaceutical developers 
• Retailers and distributors 

Business Impact

Preparing For Regulatory Evolution

Companies must adopt a proactive approach rather than waiting for final legislation.

1. Conduct Scientific & Toxicological Assessments

• Dose-response studies 
• Safety evaluations 
• Long-term exposure analysis 

2. Strengthen Compliance Frameworks

• Aligning with FDA expectations 
• Implement robust documentation 
• Maintain audit readiness 

3. Invest In Quality & Testing Systems

• Third-party lab testing 
• Batch consistency validation 
• Contaminant screening 

4. Monitor Regulatory Developments

• Track FDA announcements 
• Engage with industry bodies 
• Prepare for rapid changes 

5. Develop Flexible Market Strategies

• Avoid high-risk product categories 
• Focus on Compliant Applications 
• Plan for future regulatory shifts 

Advanced Compliance Strategies for Competitive Advantage

1. Regulatory Intelligence Systems

• Real-time monitoring of FDA updates 
• Early adaptation to policy changes 

2. Digital Compliance Infrastructure

• Blockchain traceability 
• Digital batch records 
• Transparent supply chains 

3. Clinical & Scientific Validation

• Invest in clinical trials 
• Generate safety data 
• Support regulatory submissions 

4. Global Regulatory Alignment

• Aligning with EU, UK, and international CBD policies 
• Enable cross-border expansion 

Challenges In CBD Regulatory Compliance

Strategic Benefits of Early Compliance

Organizations that prepare early will gain:

• Faster market entry once regulations are finalized 
• Reduced legal and enforcement risks 
• Stronger brand credibility 
• Increased investor confidence 
• Sustainable long-term growth 

Maven Regulatory Solutions: Your CBD Compliance Partner

Maven Regulatory Solutions provides expert support for navigating complex CBD regulations in the U.S. and global markets.

Our Services

• FDA Regulatory Strategy Development 
• Toxicology & Safety Assessments 
• Product Classification & Pathway Analysis 
• Labeling & Compliance 
• GMP & Quality System Consulting 
• Global Regulatory Intelligence 

Planning to enter or expand in the CBD market?

• Ensure FDA-compliant product strategies
• Strengthen safety and toxicology data
• Prepare for future regulatory pathways
• Minimize legal and compliance risks
• Build a future-ready CBD portfolio

Partner with Maven Regulatory Solutions today

Conclusion: The Future of CBD Regulation

The FDA’s position on CBD reflects a cautious, science-first approach.

Key Takeaways

• CBD remains restricted in food and supplements 
• Safety concerns are the primary regulatory barrier 
• Congressional action is required for a new pathway 
• Compliance readiness is essential for future success 

The future of CBD regulation will be:

• Science-driven 
• Highly regulated 
• Data-dependent 

Companies that invest in compliance, research, and transparency today will lead tomorrow’s CBD market.

Frequently Asked Questions 

1. Is CBD legal in food products in the U.S.?
No, the FDA does not currently allow CBD in food.

2. Why did the FDA reject CBD supplement petitions?
Due to insufficient safety and dosage data.

3. What is Epidiolex?
An FDA-approved CBD-based drug for epilepsy.

4. What is the biggest regulatory challenge?
Lack of long-term safety data.

5. Will CBD regulations change?
Yes, a new pathway is expected through Congress.

6. Can CBD be used in cosmetics?
Yes, but with restrictions and no therapeutic claims.

7. What should companies do now?
Invest in safety studies and compliance systems.

8. When will new regulations be finalized?
Timeline depends on Congressional action.